Catherine Sohn Joins Ariel Board of Directors

Apr 5, 2012

Ariel Pharmaceuticals, Inc. announced today that Catherine Angell Sohn, Pharm.D., CLP, has been appointed as an independent director to Ariel's board of directors. Dr. Sohn is an industry veteran who was most recently senior vice president of worldwide business development and strategic alliances for GSK.

Ariel Pharmaceuticals, Inc. Enters Cooperative Research & Development Agreement (CRADA) With U.S. Military for its Hemorrhagic Shock Treatment

Jan 17, 2012

Ariel Pharmaceuticals announced it has signed a cooperative research & development agreement (CRADA) with the United States Army Medical Research and Material Command for late-stage preclinical development of AP-1100 for hemorrhagic shock.

SVB Financial Group interview with Steve Orndorff

Nov 1, 2011

Ariel Acquires Hemorrhagic Shock Technology from University of Minnesota

Oct 17, 2011

Ariel Pharmaceuticals, Inc. announced that it has in-licensed Tamiasyn™ (AP-1100) for the treatment of hemorrhagic shock from the University of Minnesota.

New Additions to the Ariel Board of Directors and SAB

Oct 3, 2011

Ariel Pharmaceuticals, Inc. announced that Perry B. Molinoff, M.D., has been appointed as independent director of its board of directors and Professor Stanton Newman, Ph.D., has joined as chairman of the company's scientific advisory board.

Ariel Acquires Novel Compound for Acute Migraine

Sep 21, 2011

Ariel Pharmaceuticals, Inc. announced that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine and osteoarthritis from the specialist healthcare company BTG International Ltd (LSE: BGC).